A Multicenter, Open-Label Phase I/II Trial of the Safety and Efficacy of the dHER2 Recombinant Protein Combined With Immunological Adjuvant AS15 in Patients With Metastatic Breast Cancer Overexpressing HER2/Neu.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Cancer vaccine HER-2 neu (Primary) ; AS15
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Oct 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
- 13 Oct 2009 Actual end date (1 Sep 2009) added as reported by ClinicalTrials.gov.
- 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.